Search

Your search keyword '"Leen, C"' showing total 47 results

Search Constraints

Start Over You searched for: Author "Leen, C" Remove constraint Author: "Leen, C" Topic anti-hiv agents Remove constraint Topic: anti-hiv agents
47 results on '"Leen, C"'

Search Results

1. Virological outcomes of boosted protease inhibitor-based first-line ART in subjects harbouring thymidine analogue-associated mutations as the sole form of transmitted drug resistance.

2. Antiretrovirals, Fractures, and Osteonecrosis in a Large International HIV Cohort.

3. Host, disease, and antiretroviral factors are associated with normalization of the CD4:CD8 ratio after initiating antiretroviral therapy.

4. Incomplete reversibility of estimated glomerular filtration rate decline following tenofovir disoproxil fumarate exposure.

5. Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring.

6. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012.

7. Biomarkers to monitor safety in people on art and risk of mortality.

8. Does discordancy between the CD4 count and CD4 percentage in HIV-positive individuals influence outcomes on highly active antiretroviral therapy?

9. Long-term trends in CD4 cell counts and impact of viral failure in individuals starting antiretroviral therapy: UK Collaborative HIV Cohort (CHIC) study.

10. Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study.

11. Antiretroviral therapy CNS penetration and HIV-1-associated CNS disease.

12. Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populations.

13. Discordant responses on starting highly active antiretroviral therapy: suboptimal CD4 increases despite early viral suppression in the UK Collaborative HIV Cohort (UK CHIC) Study.

14. Factors influencing lopinavir and atazanavir plasma concentration.

15. Virological response to initial antiretroviral regimens containing abacavir or tenofovir.

16. Treatment switches after viral rebound in HIV-infected adults starting antiretroviral therapy: multicentre cohort study.

17. Changes in outcome of persons initiating highly active antiretroviral therapy at a CD4 count less than 50 Cells/mm3.

18. Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression?

19. Patterns and predictors of the use of different antiretroviral drug regimens at treatment initiation in the UK.

20. Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication.

21. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy.

22. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy.

23. Salvage therapy with abacavir plus efavirenz or nevirapine in HIV-1-infected persons with previous nucleoside analogue and protease inhibitor use.

25. Combination therapy for HIV: the effect on inpatient activity, morbidity and mortality of a cohort of patients.

27. Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy

28. Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents

29. Prevalence and Outcomes for Heavily Treatment-Experienced Individuals Living With Human Immunodeficiency Virus in a European Cohort

30. Observational cohort study of rilpivirine (RPV) utilization in Europe

31. Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response:a sub-study of the NEAT001/ANRS143 randomized trial

32. Long‐term effectiveness of recommended boosted protease inhibitor‐based antiretroviral therapy in Europe

33. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study

34. Virological outcomes of boosted protease inhibitor-based first-line ART in subjects harbouring thymidine analogue-associated mutations as the sole form of transmitted drug resistance

35. Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort

36. Virological failure and development of new resistance mutations according to CD4 count at combination antiretroviral therapy initiation

37. Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression : A prospective cohort study

38. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study

39. Circulating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control Study

40. Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study

41. Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study

42. Changing utilization of Stavudine (d4T) in HIV-positive people in 2006-2013 in the EuroSIDA study

43. Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial

44. Increased risk of cardiovascular disease (CVD) with age in HIV-positive men: a comparison of the D:A:D CVD risk equation and general population CVD risk equations

45. Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study

46. Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy

47. Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort study

Catalog

Books, media, physical & digital resources